UK shareholder meetings calendar - next 7 days
6th May 2025 14:14
| Price | 221.00p on 09-05-2025 at 12:05:12 |
|---|---|
| Change | 0.00p 0% |
| Buy | 224.00p |
| Sell | 218.00p |
| Buy / Sell HCM Shares | |
| Last Trade: | Buy 700.00 at 223.394p |
| Day's Volume: | 1,223 |
| Last Close: | 221.00p |
| Open: | 221.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 0.00p - 0.00p |
| 52wk Range: | 187.50p - 352.00p |
| Market Capitalisation: | £1,889m |
| VWAP: | 220.7072p |
| Shares in Issue: | 855m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 700 | 223.394p | Ordinary |
12:47:51 - 09-May-25 |
| Sell* | 17 | 218.30p | Ordinary |
10:48:03 - 09-May-25 |
| Sell* | 500 | 217.00p | Ordinary |
08:47:15 - 09-May-25 |
| Unknown* | 0 | 224.00p | SI Trade |
08:12:16 - 09-May-25 |
| Sell* | 21 | 221.00p | Uncrossing Trade |
16:35:02 - 08-May-25 |
| Sell* | 34 | 220.00p | SI Trade |
15:00:36 - 08-May-25 |
| Buy* | 500 | 230.80p | Ordinary |
10:56:31 - 08-May-25 |
| Buy* | 69 | 230.00p | SI Trade |
16:29:55 - 07-May-25 |
| Unknown* | 0 | 219.00p | SI Trade |
16:29:55 - 07-May-25 |
| Sell* | 400 | 219.306p | Ordinary |
16:18:23 - 07-May-25 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 24th Apr 2025 7:00 am | RNS-R | HUTCHMED - Data to be Presented at AACR 2025 |
| 22nd Apr 2025 7:00 am | RNS-R | HUTCHMED Completes Enrollment of Phase II Study |
| 7th Apr 2025 9:30 am | RNS | 2024 Annual Report and Notice of AGM |
| 31st Mar 2025 10:30 am | RNS | Extraordinary General Meeting – Poll Results |
| 21st Mar 2025 10:00 am | RNS-R | NMPA Conditional Approval for TAZVERIK® |
| 20th Mar 2025 9:30 am | RNS | Retirement of Independent Non-executive Directors |
| 20th Mar 2025 7:00 am | RNS-R | HUTCHMED Highlights Savolitinib SAVANNAH Phase II |
| 19th Mar 2025 1:45 pm | RNS-R | Publication of Form 20-F |
| 19th Mar 2025 11:00 am | RNS | 2024 Final Results and Business Updates |
| 19th Mar 2025 7:00 am | RNS-R | Phase II/III Study of Fruquintinib and Sintilimab |